Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page



Aridis Pharmaceuticals Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™.


Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia.


Aridis Pharmaceuticals CEO Invited to Speak on Infectious Disease Panel at 2016 Anti-Infectives Rx Conference.


Aridis Pharmaceuticals Expands the Company’s Clinical Advisory Board; Adds Three Industry Veterans with Unique Expertise in the Field.


Aridis Pharmaceuticals Strengthens Board of Directors with Former Wyeth (now Pfizer) President of R&D Robert Ruffolo, Jr..


Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016.

Immunotherapy Using Monoclonal Antibodies is the Next Frontier in Fighting Infections
Featured Product

The biggest threat to global health today is antibiotic resistance. Aridis’ solution is to leverage the natural human immune system in the form of monoclonal antibodies to fight infections. This novel approach is also referred to as anti-infective immunotherapy.

We have developed a broad, unrivaled portfolio of anti-infective monoclonal antibodies or mAbs that target the infecting pathogens.  Aridis has three of the most advanced monoclonal antibodies that are in or about to enter phase 2 clinical testing to address the $30B antibiotic resistance market.

Our mAb therapies are complemented by a breakthrough discovery platform called MabIgX that  allows for  discovery of rare, protective antibody producing B-cells and the rapid transition to clinical testing.    

AR-301 (SalvecinTM) is a fully human monoclonal IgG1 antibody specifically targeting S. aureus alpha-toxin. Upon binding to its target antigen AR-301 represses functional toxin pore formation leading to protection of susceptible cells of the infected host from alpha-toxin dependent destruction. Its mode of action is independent of the antibiotic resistance profile of S. aureus, hence AR-301 is active against infections caused by both antibiotic resistant (MRSA) and antibiotic sensitive (MSSA) strains. Intravenous administration of AR-301 mAb to mice with acute pneumonia caused by S. aureus resulted in reduced bacterial loads and significantly improved survival rates. An international Phase 1/2a human clinical trial evaluating the safety and efficacy of AR-301 in hospital-acquired pneumonia (HAP) and ventilator- associated pneumonia (VAP) patients is nearing completion, with data expected in the second half of 2016.

More >>

More >>


Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home